Liso-cel Demonstrates Significant Response in Relapsed/Refractory Marginal Zone Lymphoma
核心洞察
Bristol Myers Squibb (搜索)'s liso-cel achieved a statistically significant and clinically meaningful overall response rate in patients with relapsed or refractory marginal zone lymphoma (搜索).
The Phase 2 trial results highlight the potential of liso-cel as an effective treatment option for this challenging patient population.
The data were presented at the 2025 Tandem Meetings, showcasing advancements in cell therapy for hematological malignancies.
Bristol Myers Squibb (搜索)'s lisocabtagene maraleucel (liso-cel), a CAR T-cell therapy, has demonstrated a statistically significant and clinically meaningful overall response rate (ORR) in a Phase 2 trial cohort of patients with relapsed or refractory (R/R) marginal zone lymphoma (搜索) (MZL). The data, presented at the 2025 Tandem Meetings, signal a potential new treatment avenue for this difficult-to-treat patient population.
The study evaluated the efficacy and safety of liso-cel in patients with R/R MZL who had failed prior lines of therapy. Marginal zone lymphoma (搜索) is a slow-growing B-cell lymphoma (搜索), and while initial treatment can be effective, many patients relapse, necessitating further interventions. The trial's primary endpoint was ORR, a measure of the proportion of patients achieving a complete or partial response to the therapy.
Liso-cel works by genetically modifying a patient's own T cells to target the CD19 (搜索) protein found on lymphoma (搜索) cells. These modified T cells, now equipped to recognize and destroy cancer cells, are infused back into the patient. This approach has shown promise in other B-cell lymphomas, leading to its investigation in MZL.
The results indicated a notable ORR, suggesting that liso-cel could offer a valuable option for patients with R/R MZL who have limited treatment alternatives. Further details from the trial, including the duration of response and safety profile, are anticipated to provide a more complete picture of liso-cel's potential in this setting. The full data set will be submitted for presentation at an upcoming medical meeting and will be discussed with regulatory agencies.
The development of CAR T-cell therapies like liso-cel represents a significant advancement in the treatment of hematological malignancies, offering the potential for durable remissions in patients who have exhausted other treatment options. The results of this Phase 2 trial support further investigation of liso-cel in MZL and other B-cell lymphomas.